The cuticular growing factor receptor ( EGFR ) is known to play an of import function in signalling tracts in tumour generation. In legion malignant neoplastic diseases, up ordinance of EGFR contributes to break tumor endurance and growing. In the last twosome of old ages, there have been a figure of new drugs targeted at the EGFR and barricading the receptor has proven to be a manner to supply intervention against solid tumor. , One of these agents targeted at the EFGR is cetuximab ( Erbitux, Bristol-Myers Squibb and ImClone Systems ) . Cetuximab is a chimeral mouse-human IgG1 monoclonal antibody against the extracellular sphere of the receptor. Being chimeral, it is composed of a human Fc-part and a murine Fab-part. The drug is approved for the intervention of colorectal malignant neoplastic disease and squamous-cell carcinoma of the caput and cervix. Different side-effects are known for cetuximab, of which 1 is terrible hypersensitivity reactions. These reactions were thought to happen in less than 3 % of the patients given the drug. However, in certain parts of the USA there were studies of much higher prevalence of these reactions. Chung et Al. published a recent survey in which they addressed this issue.
In several provinces, the figure of people sing hypersensitivity reactions after having cetuximab was higher than expected. Up to 22 % of patients having cetuximab in Tennessee and North Carolina experienced hypersensitivity reactions. Such reactions occurred within proceedingss after the first disposal of the drug and was compatible with IgE-mediated anaphylaxis.3, The survey of Chung et Al. focused on the hypothesis that the hypersensitivity reaction was mediated by preexistent IgE antibodies against cetuximab.
Serum from patients who received cetuximab with or without a attendant hypersensitivity reaction ( from Tennessee, North Carolina and Arkansas ) were studied. A sum of 25 patients from a group of 76 had had such a reaction. The serum was compared to command patients who were healthy or had malignant neoplastic disease of the caput and cervix. Two groups of control patients came from countries where the rate of patients sing a hypersensitivity reaction after cetuximab was less than 1 % . Serum of six patients, who had had a terrible reaction, was used to develop checks.
The consequences show a high correlativity between the presence of preexistent IgE antibodies against cetuximab and the happening of hypersensitivity reactions. The antibodies against cetuximab were directed at the Fab part of the heavy concatenation and were found to be specific for galactose- & A ; alpha ; -1,3-galactose.
The survey concludes that the terrible hypersensitivity reactions after having cetuximab were caused by preexistent IgE antibodies against the galactose- & A ; alpha ; -1,3-galactose oligosaccharide on the Fab part of cetuximab. There is a important difference in the prevalence of preexistent antibodies against cetuximab. The sou’-east of the USA has a higher figure of people who already have such antibodies in comparing to other parts of the USA. The research is hereby the first to supply a mechanism for the anaphylactic reaction that some people experience after cetuximab is administered.
Although this survey raises several inquiries, it besides provides replies refering the anaphylactic reactions. And being the first to print a survey on the presence of preexistent IgE antibodies against an antibody-based remedy, it is of importance non merely to doctors, but besides to the pharmacological industry. A restriction in the survey is the little figure of patients with a terrible hypersensitivity reaction and IgE antibodies in their blood, chiefly because the prevalence of the antibodies is part specific. More surveies should be done, to happen out if higher Numberss of anaphylactic reactions are besides present in other parts and if they are caused by the same IgE antibody as in Tennessee. More remains unreciprocated. There are already antibodies present before cetuximab is given, which means there is a cross-reaction, but the beginning of the primary sensitisation is unknown. Result show that the antibody reacts with galactose- & A ; alpha ; -1,3-galactose on cat, Canis familiaris, beef and porc proteins. However, consumption of beef or porc leads to either a delayed reaction or no reaction at all. Why there is no allergic reaction or simply a delayed reaction remains unreciprocated in the survey. It is possible that the divalent presentation of the antigenic determinant is the cause of the anaphylactic reactions, but this needs farther probe.
This research leads to new positions. Now that it has been demonstrated how preexistent IgE antibodies can do a terrible reaction directed against a curative monoclonal antibody, the pharmaceutical industry can utilize this information in the production of new chimeral antibodies. New agents should be tested and bing merchandise labels should be adjusted. The pharmaceutical industry could prove freshly produced monoclonal antibodies which have caused hypersensitivity with saccharide groups with sera of patients with different allergic reactions against workss or pollen to see if cross-reactions take topographic point.
The terrible hypersensitivity reaction is, although treatable, a serious side consequence of cetuximab, particularly if the prevalence is as as seen in the Tennessee part. By supplying the grounds that preexistent IgE is the cause of the terrible reaction, doctors in bad parts can take this into history when ordering cetuximab and carry out a showing blood trial for the specific IgE antibodies before administrating the drug, thereby forestalling a terrible reaction in the patient. Numerous drugs are now being studied in clinical tests, of which some are to the full human monoclonal antibodies, such as panitumumab. Such agents can be the reply to IgE mediated responses against oligosaccharides on the murine Fab-portion.
In decision the survey done by Chung et Al. provides a plausible mechanism for the anaphylactic reactions and hopefully sheds light on a job which is non universally recognised, therefore, thereby lending greatly to the apprehension of the anaphylactic side effects of cetuximab. However, there are inquiries raised after this survey for which they did non supply sufficient replies. What causes the part specific prevalence of antibodies against cetuximab and where do they come from? Why do n’t they do a rapid oncoming of allergic symptoms after consumption of beef and porc even though they are cross-reactive? Does primary sensitisation non ensue in clinical reactions because the galactose- & A ; alpha ; -1,3-galactose is present in that beginning in a monovalent signifier merely? Although one of import inquiry is answered, there are many new inquiries raised. Acerate leaf to state, farther research is necessary.
Baselga J. New engineerings in cuticular growing factor receptor-targeted malignant neoplastic disease therapy. Signal. 2000 1:12-21.
Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growing factor receptor monoclonal antibodies in malignant neoplastic disease intervention. Cancer Treat Rev. 2009 Jun ; 35 ( 4 ) :354-63.
O’Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM. High incidence of cetuximab-related extract reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007 Aug 20 ; 25 ( 24 ) :3644-8.
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA. Cetuximab-induced anaphylaxis and IgE particular for galactose-alpha-1,3-galactose. N Engl J Med. 2008 Mar 13 ; 358 ( 11 ) :1109-17.
Sampson HA, Mu & A ; ntilde ; oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O’Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and direction of anaphylaxis: drumhead study — Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006 Feb ; 117 ( 2 ) :391-7.
Wu M, Rivkin A, Pham T. Panitumumab: human monoclonal antibody against cuticular growing factor receptors for the intervention of metastatic colorectal malignant neoplastic disease. Clin Ther. 2008 Jan ; 30 ( 1 ) :14-30.